Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women

被引:2
|
作者
Upson, Kristen [1 ]
Harmon, Quaker E. [2 ]
Heffron, Renee [3 ,4 ]
Hall, Janet E. [5 ]
Wise, Lauren A. [6 ]
Wegienka, Ganesa [7 ]
Tokar, Erik J. [8 ]
Baird, Donna D. [2 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, 909 Wilson Rd,Room 601, E Lansing, MI 48824 USA
[2] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA
[3] Univ Washington, Dept Global Hlth, Seattle, WA USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[5] NIEHS, Clin Res Branch, Res Triangle Pk, NC USA
[6] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA
[7] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA
[8] NIEHS, Stem Cells Toxicol Grp, Natl Toxicol Program Lab, Div Natl Toxicol Program, Res Triangle Pk, NC USA
基金
美国国家卫生研究院;
关键词
HUMAN VAGINAL HISTOLOGY; BONE-MINERAL DENSITY; HORMONAL CONTRACEPTION; MOBILIZATION; PERIMENOPAUSAL; PREMENOPAUSAL; OSTEOPOROSIS; PREGNANCY; EFFICACY; THERAPY;
D O I
10.1289/EHP7017
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead. OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations. METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23-35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent difference in blood lead concentrations and 95% confidence intervals (CI) between current DMPA users and nonusers using multivariable linear regression. RESULTS: Geometric mean blood lead concentration was 0:69 lg=dL (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, and history of medical conditions or current medication use associated with bone loss. DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoffs between the adverse effects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy.
引用
收藏
页码:117004 / 1
页数:7
相关论文
共 50 条
  • [1] Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women
    Harmon, Q. E.
    Baird, D. D.
    HUMAN REPRODUCTION, 2015, 30 (06) : 1499 - 1504
  • [2] MEDROXYPROGESTERONE ACETATE LEVELS AMONG WOMEN USING DEPOT MEDROXYPROGESTERONE ACETATE IN THE FEM-PREP TRIAL
    Nanda, K.
    Callahan, R.
    Taylor, D.
    Agot, K.
    Dorflinger, L.
    CONTRACEPTION, 2014, 90 (03) : 313 - 313
  • [3] USE OF INJECTABLE DEPOT MEDROXYPROGESTERONE ACETATE IN LACTATING INDIAN WOMEN
    SATHYAMALA, C
    SHAH, P
    JAIN, Y
    BHARGAVA, R
    LANCET, 1994, 344 (8915): : 134 - 135
  • [4] Incidence of galactorrhea in young women using Depot-Medroxyprogesterone acetate
    Omar, Hatim A.
    Zakharia, Rana M.
    Kanungo, Shibani
    Huff, Marlene
    McClanahan, Kimberly
    THESCIENTIFICWORLDJOURNAL, 2006, 6 : 538 - 541
  • [5] Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women
    Ratchanon, S
    Taneepanichskul, S
    OBSTETRICS AND GYNECOLOGY, 2000, 96 (06): : 926 - 928
  • [6] THE CONTRACEPTIVE USE OF DEPOT MEDROXYPROGESTERONE ACETATE
    HICKEY, M
    FRASER, I
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1995, 38 (04): : 849 - 858
  • [7] Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial
    Nanda, Kavita
    Callahan, Rebecca
    Taylor, Douglas
    Wang, Meng
    Agot, Kawango
    Jenkins, David
    Van Damme, Lut
    Dorflinger, Laneta
    CONTRACEPTION, 2016, 94 (01) : 40 - 47
  • [8] Effects of depot medroxyprogesterone acetate on resting energy expenditure in young women.
    Pelkman, CL
    Heinbach, RA
    Rolls, BJ
    FASEB JOURNAL, 1999, 13 (05): : A1028 - A1028
  • [9] Use of depot medroxyprogesterone acetate in Thai adolescents
    Chotnopparatpattara, P
    Taneepanichskul, S
    CONTRACEPTION, 2000, 62 (03) : 137 - 140
  • [10] USE OF DEPOT MEDROXYPROGESTERONE ACETATE AND FRACTURE RISK
    Meier, C.
    Kraenzlin, M. E.
    Meier, C. R.
    Brauchli, Y. B.
    Jick, S. S.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 10 - 10